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Wemapped the cytokine response to hematopoietic stem cell transplantation (HSCT) by assaying 51 cytokines
and chemokines eachweek for 100 days in 51 children receiving allogeneic (n¼ 44) or autologous HSCT (n¼ 7).
Assay valueswere reported asmeanﬂuorescence intensity (MFI). Log transformation convertedMFI to clinically
relevant measures (ie, pg/mL). We searched for potential markers of transplant complications by using mixed
treatment by subject analysis of variance. Global cytokine secretion in HSCT recipients was signiﬁcantly lower
than in concurrent control patients (n¼ 11). Coincidentwith the nadir inWBC count, the concentration ofmany
cytokines declined further by the second and third week. All analytes (except monokine induced by gamma
interferon [MIG]) subsequently rebounded byweek4 (coincidentwith engraftment and recoveryofWBC count)
but often still remained well below control levels. Concurrent with the collective nadir of multiple cytokines,
monocyte chemoattractant protein 1 (MCP-1), growth-regulated oncogene alpha (GRO-a), and leptin surged
duringweeks 2 to4.High levels of leptinpersisted throughout the100post-transplant days. Also duringweeks 2
to 4, hepatocyte growth factor (HGF) and IL-6 surged in children with complications but not in those without
complications. The peak in HGFwasmore pronounced in veno-occlusive disease (VOD). HGF and IL-6 secretion
rose at least 2 weeks before the clinical diagnosis of VOD or graft-versus-host disease (GVHD). From week 4
onward in all groups, the MFI of the cytokine resistin increased to 5 to 15 times above concurrent control. HGF
has now emerged in 3 or more biomarker discovery efforts for GVHD (and in our population for VOD as well).
HGF (with or without IL-6) should be investigated as a potential predictive biomarker of VOD or GVHD. Alter-
natively, the hyperinﬂammatory “signature” provided by a multicytokine assay may be predictive.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION informed consent in accordance with a protocol approved by the Institu-
Allogeneic hematopoietic stem cell transplantation (HSCT)
induces changes in the cytokine milieu that may contribute to
theminor andmajor complications experienced bymany HSCT
recipients. We mapped the cytokine response to trans-
plantation in 51 children by assaying 51 cytokines and chemo-
kines each week for the ﬁrst 100 days after the transplantation
procedure. Longitudinal data of this sort had previously been
obtained for only a handful of cytokines and over a limited time
period.With aggregate datawe propose a characteristic pattern
or “signature” of cytokine secretion after transplantation and
suggest potential candidatemarkers and therapeutic targets for
hepatic veno-occlusive disease (VOD; sinusoidal obstruction
syndrome) and graft-versus-host disease (GVHD).
METHODS
Eligible subjects were children (0 to 18 years of age) who were
impending recipients of HSCT at Children’s Hospital Los Angeles and at
Lucile Packard Children’s Hospital at Stanford University. Fifty-one children
(age 8.7  5.9 years, 30 boys, 21 girls) were enrolled after obtaining parentaledgments on page 368.
quests: Joseph DiCarlo, MD, Anesthesi-
ren’s Hospital Los Angeles, 4650 Sunset
90027.
sc.edu (J. DiCarlo).
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13.11.026tional Review Boards at both institutions. Forty-four received allogeneic
transplants, and 7 were recipients of an autologous HSCT. Their primary
diagnoses are listed in Table 1. There were 5 deaths: 2 from relapsed leu-
kemia and 3 from respiratory failure.
Baseline epidemiological data included age, primary diagnosis, and type
of transplant. Data collected each week throughout the study period
included respiratory rate, oxygen saturation, use of supplemental oxygen (if
any; concentration, ﬂow), documentation of infection (if any), WBC count
and differential, and C-reactive protein. The diagnosis of VOD was guided by
the Seattle criteria, with at least 2 of 3 clinical features apparent less than
30 days after transplantation: (1) jaundice, (2) hepatomegaly with right
upper quadrant pain/tenderness, and (3) ascites and/or unexplained weight
gain (Table 2) [1]. The Keystone criteria were used to grade GVHD [2].
A whole blood sample not exceeding 2 mL was collected on day 0 just
before the transplantationprocedure, thenweekly duringhospitalization, and
thereafter at the time of other standard transplant laboratory procurements
(ie, some weeks after day 30 were skipped in some recipients), up to a
maximum of 105 days post-transplantation. Blood was collected in a red-top
tube (ie, without additives) and stored upright at room temperature for 20 to
30minutes to form a clot. It was then centrifugedwithin 2 hours of collection
at 1200 relative centrifugal force for 10 minutes at room temperature. The
supernatant was collected, avoiding aspiration close to the clot. To minimize
future damage from freezeethaw cycles, the supernatant was divided into
aliquots, labeled, and placed on ice (4C) before freezing at e80C.
Luminex Multiplex Cytokine Assay and Statistical Methods
Anassayofapanelofcytokineswasperformedaccording tomanufacturer’s
recommendations (Luminex multiplex cytokine kits; Panomics/Affymetrix,Transplantation.
Table 1
Diagnoses in Children (N ¼ 51) Receiving HSCT
Allogeneic Transplantation Autologous Transplantation
Acute lymphocytic leukemia (5) Hodgkin lymphoma (2)
Acute myelogenous leukemia (10) Neuroblastoma (3)
Biphenotypic leukemia (2) Retinoblastoma (1)
Anaplastic large cell lymphoma (1) Rhabdomyosarcoma (1)
Aplastic anemia (3)
Myelodysplastic syndrome (5)
Fanconi anemia (2)
Sickle cell disease (2)
Thalassemia (3)
Histiocytosis (1)
Mucopolysaccharidosis (1)
Cartilage hair hypoplasia (1)
Hemophagocytic lymphohistiocytosis (1)
X-linked adrenoleukodystrophy (1)
X-linked lymphoproliferative disease (1)
Severe combined immune deﬁciency (3)
CD40 ligand deﬁciency (1)
Chediak-Higashi disease (1)
J. DiCarlo et al. / Biol Blood Marrow Transplant 20 (2014) 361e369362Santa Clara, CA). Samples (25 mL) in duplicate were added to a 96-well
ﬁlter plate preconﬁgured with a panel of anticytokine antibodies covalently
linked to unique polystyrene beads. Standards (7-point dilutions) and controls
were added at this time. The plate was incubated for 90 minutes at room
temperature in the darkwhile shaking at 500 rpm. The platewas then vacuum
aspirated and washed 3 times with 140 mL of wash buffer to remove unbound
antigen sample. Biotinylated detection antibody solution was then added to
the bead mixture in each well (25 mL) and incubated for 30 minutes with
shaking at room temperature as above. Themixturewas vacuumaspirated and
washed 3 times to remove excess detector antibody. Streptavidin-PE (50 mL)
was added to the mixture and incubated for 30 minutes with shaking at
room temperature. The mixture was vacuum aspirated, washed 3 times,
resuspended in reading buffer (120 mL), and incubated for 3 minutes at room
temperature with shaking. The 96-well plate was then transferred to the
Luminex reader (Luminex, Austin TX) for quantitative analysis.
The xMAP technique (Luminex) blends sandwich immunoassay with
ﬂuorescent beadebased technology. Polystyrene microspheres (5.5-mm
diameter) are each ﬁlled with a speciﬁc red/infrared ﬂuorescent dyemixture
(with 100 possible mix combinations). Each bead is also coated with speciﬁc
bioassay reagents (eg, antibodies against IL-6). This combination facilitates
the quantiﬁcation of up to 500 different analytes in a single microtiter well.
Individual cytokines were identiﬁed and classiﬁed by their bead color
using red laser excitation, and cytokine levels were quantiﬁed via green
laser excitation. Digital images of the bead array were captured after laser
excitation using a Pixel CCD camera (Luminex, Austin TX) and were pro-
cessed on a computer workstation. Data were then imported into BeadView
software and analyzed to obtain standard curves and to quantify cytokine
levels. Assay values were reported as mean ﬂuorescence intensity (MFI). Log
transformation converts MFI to clinically relevant measures (eg, pg/mL),
which can introduce a degree of error [3]. We therefore conducted our
analysis using MFI data; we also report pg/mL conversions to facilitate
comparison with existing literature.Table 2
Diagnosis of VOD Guided by Seattle Criteria
Patient Bilirubin
(mg/dL)
Baseline (Max) Ascites Ultrasound Onset
(d)
14moM 2.9 10 kg (12.2 kg) Yes Hepatomegaly,
ascites
8
14 mo F .8 10.3 kg
(11.5 kg)
Yes Hepatomegaly,
ascites
7
8 mo F* 7.7 5.2 kg (9.7 kg) Severe Hepatomegaly,
ascites
14
12 yr M 3.5 45.7 kg (50 kg) Yes Hepatomegaly,
ascites
56
12 yr M 1.9 34.1 kg
(38.8 kg)
Yes Hepatomegaly,
ascites
56
Diagnosis of VOD was guided by the Seattle criteria [1], with at least 2 of 3
clinical features apparent < 30 days after transplantation: (1) jaundice, (2)
hepatomegaly with right upper quadrant pain/tenderness, and (3) ascites
and/or unexplained weight gain.
* One child was diagnosed with GVHD as well.Statistical Analysis
We identiﬁed potential markers of transplant complications by using
mixed treatment by subject analysis of variance, with the repeatedmeasures
of cytokine MFI as a “within-subjects” factor and categories (ie, uncompli-
cated, VOD, GVHD) as the “between-subjects” factor.
Aggregate cytokine data from transplant recipients were referenced
against standards established with sera from a control group (11 healthy
subjects ages 13 to 40 years), which were analyzed concurrently with the
study samples. Data from transplant recipients were further subdivided into
3 groups for comparative analysis (GVHD, n ¼ 11; VOD, n ¼ 5; and un-
complicated, n ¼ 33); 1 child developed both diagnoses (Tables 2-3). A
fourth subdivision, respiratory insufﬁciency, had too few recipients (n ¼ 3)
for meaningful analysis; Found patterns were used to propose a character-
istic cytokine “signature” over the ﬁrst 100 days after HSCT.
RESULTS
Figure 1 maps theWBC count (y-axis; cells per microliter)
over theﬁrst 100 days afterHSCT. Counts declinedpredictably
within the ﬁrst 1 to 2 weeks of transplantation (x-axis) and
then recovered over time. Recovery in WBC counts occurred
more rapidly in children who developed GVHD or VOD.
Coincident with the nadir in WBC count, the concentra-
tion of many cytokines declined by the second and third
week: CD40, ﬁbroblast growth factor-b, intercellular adhe-
sion molecule-1, IL-1a, IL-1b, IL-2, IL-5, IL-4, IL-7, IL-12P40,
IL-12P70, IL-13, IL-15, IL-17, interferon, interferon gamma-
induced protein-10 (IP-10), leptin, monocyte chemotactic
protein-3 (MCP3), monokine induced by gamma-interferon
(MIG), macrophage inﬂammatory protein-1b (MIP1b), nerve
growth factor (NGF), plasminogen activator inhibitor-1
(PAI-1), platelet-derived growth factor-BB (PDGFBB), RANTES
(regulated on activation, normal T cell expressed and
secreted), resistin, sFAS ligand, tumor necrosis factor alpha
(TNF-a), transforming growth factor (TGF)-a, TGF-b, TNF-
related apoptosis-inducing ligand (TRAIL), and vascular cell
adhesion molecule (VCAM1). All these analytes (except MIG)
subsequently rebounded by week 4 (coincident with
engraftment and recovery of the WBC count). Depression of
several cytokines can be seen in Figure 2.
Coincident with the collective nadir of multiple cytokines,
3 entities surged across all groups during weeks 2 to 4:
MCP-1, GRO-a (growth-regulated oncogene), and leptin
(Figure 3). High levels of leptin persisted throughout the 100
post-transplant days.
Also during weeks 2 to 4, 2 cytokines surged in children
with complications but not in those without complications:
hepatocyte growth factor (HGF) and IL-6. The peak in HGF
was more pronounced in VOD (Figures 4-5). IL-6 was
elevated in children who ultimately were diagnosed with
VOD or GVHD, whereas it remained at or below control levels
in children without complications. C-reactive protein was
elevated inconsistently in VOD and GVHD despite being
considered a surrogate for IL-6.
Baseline granulocyte macrophage colony-stimulating fac-
tor (GM-CSF) was higher in children who eventually devel-
oped GVHD (MFI 25  13 versus 16  11); GM-CSF was not
administered therapeutically in any patient. Five children
received exogenous granulocyte colony-stimulating factor
(G-CSF). In these children, MFI for GRO-a and MCP-1 were
statistically higher than in childrenwho did not receive G-CSF
(P< .01).Oneof theG-CSFrecipientsdevelopedvaso-occlusive
disease. Fromweek4onward inall groups, secretionof resistin
increased to 5 to 15 times above concurrent control.
DISCUSSION
We have assayed 51 cytokines and chemokines in serum
from 51 children, collected each week for 100 days after
Table 3
Diagnosis of GVHD Guided by Keystone Criteria
Patient Diagnosis Transplant GVHD Grade Onset (d)
11 yr F ALL 9/10 unrelated Cutaneous I 14
9 yr M ALL 10/10 matched Cutaneous I 28
8 mo F* AML, Fanconi 4/6 antigen
3/6 allele cord
Cutaneous II 35
15 yr F pre-B cell ALL 10/10 unrelated Cutaneous I 35
4 yr F ALL 6/6 antigen
4/6 allele cord
Cutaneous I 77
17 yr M ALL Haplo-anergy
HPC, T cells
Cutaneous II 17
2 yr M Hemophagocytic lymphohistiocytosis 9/10, 9/10 unrelated Cutaneous II 23
17 yr F Sickle cell beta-thalasemia 10/10, 10/10 unrelated Cutaneous I 33
12 yr M AML 5/10, 5/10 haploidentical Gastrointestinal II 60
1 yr M CD40 ligand deﬁciency 10/10, 9/10 unrelated cutaneous II 27
13 yr M AML 10/10, 9/10 half-sibling cutaneous I 52
ALL indicates acute lymphocytic leukemia; AML, myelocytic; HPC, hematopoietic progenitor cell.
The diagnosis of GVHD was guided by the Keystone criteria [2].
* One child was diagnosed with VOD as well.
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from standards established in a concurrent healthy control
group. This is not surprising given the provocations involved,
particularly the preparatory ablation of marrow activity with
radiation and/or chemotherapy, followed by the introduction
of (in allogeneic transplant, foreign) immunologically active
cells. Although cytokine secretion may vary widely among
pediatric HSCT recipients (ie, standard deviations were fairly
large for many cytokines), we can detect some consistent
trends across the ﬁrst 100 days.
Global cytokine secretion in the HSCT recipient is signif-
icantly lower than in concurrent control subjects (Figure 2),
and it diminishes further in the ﬁrst 2 weeks after HSCT,
coincident with the nadir in WBC count. Although most cy-
tokines are initially quiescent, 2 entities (GRO-a and MCP-1)
surge in all groups, followed in 2weeks by leptin and resistin.
During this same quiescent period, HGF and IL-6 surge in
children who will develop VOD or GVHD but not in those
without eventual complications (Table 5; Figure 6). HGF and
IL-6 secretion rises at least 2 weeks before the clinical diag-
nosis of VOD or GVHD.Figure 1. WBC count (y-axis; cells per microliter) from all study patients (N ¼ 51) pl
rebounded more rapidly in children who developed GVHD or VOD.The most promising candidate markers for GVHD are HGF
and IL-6. Both TNF-a and IFN-a were markedly elevated in
some children with GVHD, but both were highly variable.
Children with VOD exhibit consistently lower concen-
trations of several cytokines (GM-CSF, IL-2, IL-17F, IFN-b,
PDGFBB, TGF-b) as compared with either the GVHD or un-
complicated groups, but each of these (except IFN-a) trended
well below control values in all HSCT groups. Receiver
operating characteristic curves were constructed for pre-
diction of vaso-occlusive disease. HGF, GRO- a, and MCP-1
were superior to IL-6 (Figure 7). The most promising
candidate markers for VOD are HGF and IL-6. Both VCAM1
and PAI-1 trended higher in childrenwith VOD, whereas HGF
and IL-6 weremarkedly elevated before the clinical diagnosis
of VOD.
The cytokine mean values and ranges demonstrated in
our patients are broadly similar to those reported using the
same technology in other populations [4-6]. The similarities
hold true for analytes present in high concentration as well
as those in relatively low concentrations (IL-1b, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8, IL-12p70, IL-13, IFN-g, and TNF-a).otted against number of weeks after transplantation (x-axis). Total WBC count
Figure 2. Data from children who did not develop complications after HSCT (n ¼ 33), depicting several cytokines in very low concentrations compared with normal
control subjects. This graph depicts each cytokine MFI as a multiple of the concurrent control value (ie, “control” is the horizontal line at y ¼ 1, whereas individual
cytokine MFIs are depicted either above or below that reference; eg, .2 would represent a cytokine secreted at 20% of control rate). MFI for many cytokines was well
below that of concurrently measured control subjects.
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different technologies, reference values become problematic.
For instance, in a study of multiple myeloma that used an
ELISA system, control values (in pg/mL) for epithelial
neutrophil-activating protein-78 (ENA-78), GRO-a, HGF,
and vascular endothelial growth factor (VEGF) ranged higher
than in our control patients [7,8]. The same trend was re-
ported in neonatal studies with that system [9]. Another
study using the same ELISA system reported control GRO-a
in a range much higher than in our control group [10].Figure 3. Further data from the same children who did not develop complications aft
than in concurrent control subjects. Each cytokine MFI is depicted as a multiple of the
individual cytokine MFIs are depicted as multiples of the control value; we measured
decreased secretion; eg, “.2” would represent a cytokine secreted at 20% of control rIn head-to-head studies that attempt to reconcile the 2
techniques, reported picogram concentrations of certain
analytes detected by ELISA are higher than those detected by
xMAP, whereas for others they are lower [11-13]. From these
direct comparison studies, it is apparent that absolute values
for cytokine concentrations can be directly compared be-
tween studies using similar technology but not when eval-
uating studies that use different systems; rather, trends are
reliably established by either technology, and that should be
the focus when making comparisons.er HSCT (n ¼ 33), depicting the few cytokines present in concentrations greater
concurrent control value (ie, “control” is the horizontal line at y ¼ 1, whereas
MFI values as high as 15  control baseline, whereas values below “1” denotes
ate).
Figure 4. All transplant recipients exhibited increased MFI for a limited number of cytokines. Recipients who developed VOD had HGF and IL-6 activity that was
signiﬁcantly higher than in recipients without complications. IP-10 and MCP-1 varied greatly between subjects but not between groups (noncomplication versus
GVHD versus VOD).
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young adults was a reasonable but not ideal match for the
transplantation cohort. The obvious preference would be for
age-matched healthy children. However, we set the bar high
for determining differences between transplant recipients
and control subjects (P < .01 in unpaired 2-tailed t-test).
Several cytokines met this threshold (Table 4). We tracked
each cytokine weekly over the course of 15 weeks after
transplantation. For most cytokines, ﬂux over time was
remarkably consistent; peaks would occur across the popu-
lation at roughly the same point in the transplant process.
This was not an artifact of the laboratory analysis, as samples
were batched, and a given plate held samples from disparate
weeks: for example, fromweeks 0 to 5 for patient x, weeks 3
to 8 for patient y, and weeks 11 to 14 for patient z.Figure 5. Cytokine proﬁle in children who developed GVHD (n ¼ 10). IncreasBased on the patterns detected in this analysis, cytokines
that might merit further study as potential markers of
complications include IL-6 and HGF and possibly MCP-1 and
GRO-a. IL-6 has both pro-inﬂammatory and anti-
inﬂammatory features. It is secreted by T cells and macro-
phages relatively early in the immune cascade to stimulate
an immune response, particularly during infection, burns, or
direct tissue damage. Macrophages secrete IL-6 and other
cytokines in response to speciﬁc microbial pathogen-
associated molecular patterns (eg, on Escherichia coli that
have translocated due to gastrointestinal damage early in the
transplant process) [14]. IL-6 stimulates acute phase protein
synthesis and supports neutrophil and B cell production. IL-6
has anti-inﬂammatory effects as well, inhibiting TNF-a and
IL-1 while activating IL-1RA and IL-10.es in HGF and IL-6 activity were not as high as in recipients with VOD.
Table 4
Cytokine and Chemokine Concentrations of HSCT Recipients and Healthy Control Subjects on Day of Transplantation
Cytokine (pg/mL) Control Subjects (n ¼ 11) HSCT Recipients (n ¼ 51) P
CD40 ligand 121  57 84  93 .21
ENA78 423  490 50  63 1.22
Eotaxin 18  8 17  11 .77
Fibroblast growth factor-b 4  5 1  3 <.01
G-CSF 223  375 275  456 .73
GM-CSF 57  45 23  18 <.001
GRO-a 7  4 7  5 1
HGF 11  8 53  40 <.001
Intercellular adhesion molecule-1 2503  1309 30,300  19,866 <.001
IFN-a 2  4 0  0
IFN-b 14  7 21  30 .45
IFN-g 23  13 3  4 <.001
IL-10 1  1 1  2
IL-12P70 6  4 2  2 <.001
IL-12P40 12  5 6  6 .003
IL-13 15  9 3  3 <.001
IL-15 4  7 6  8 .44
IL-17 6  3 2  2 <.001
IL-17 F 45  25 13  14 <.001
IL-1-a 1  2 2  3 .29
IL-1-b 4  3 1  1 <.001
IL-1RA 6  6 58  81 .04
IL-2 97  61 18  19 <.001
IL-4 8  5 2  2 <.001
IL-5 55  28 21  19 <.001
IL-6 2  3 1  1 .05
IL-7 101  55 39  30 <.001
IL-8 3  2 3  3 1
IP10 19  9 97  102 .014
Leptin 987  395 19,690  23,782 .012
LIF 15  9 2  2 <.001
M-CSF 1  1 0  0
MCP-1 15  7 47  45 .02
MCP-3 110  166 12  11 <.001
MIG 8  4 91  110 .02
MIP-1b 43  22 91  78 .05
MIP-1a 25  13 17  16 .13
NGF 32  17 14  14 <.001
PAI-1 1484  592 1722  738 .32
PDGFBB 723  423 165  145 <.001
RANTES 262  126 436  179 .004
Resistin 1290  653 643  678 .005
SCF 1  2 2  3
sFAS ligand 104  182 4  3 <.001
TGF-a 1  1 1  1
TGF-b 9  3 1  2 <.001
TNF-a 2  1 1  1 .004
TNF-b 1  1 1  1
TRAIL 16  8 15  11 .78
VCAM-1 616  507 3668  3083 .002
VEGF 13  8 11  10 .54
Cytokine and chemokine concentration (pcg/mL) determined algorithmically, comparing HSCT recipients the day of transplantation against healthy controls.
When control values were unexpectedly low, algorithm or assay failure was assumed; these cytokines are printed in gray type and were omitted from statistical
analysis.
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CXCL1] is produced by macrophages, neutrophils, and
epithelial cells. It participates in angiogenesis and inﬂamma-
tion and has been implicated in vaso-occlusion during he-
molytic transfusion reactions in a mouse model of sickle cell
disease [15]. Because this may be relevant to understanding
and possibly treating VOD in transplant recipients, we brieﬂy
describe this model. Hemolytic transfusion reactionwas used
to induce an acute vaso-occlusive crisis in the sickle cell
mouse. In crisis, themost dramatic elevation in cytokine levels
was noted for CXCL1 (GRO-a). Pathological changes included
leukocyte recruitment in venules, capture of circulating RBCs,
and reduction of ﬂow in venules. The infusion of recombinant
GRO-a alone could induce the acute reproduction of these
clinical and pathological ﬁndings, whereas blockade of theCXCL1 receptor, CXCR2, prevented transfusion-elicited acute
vaso-occlusive crisis. The investigators suggested that tar-
geted inhibition of CXCL1 (GRO-a) and/or CXCR2 might
emerge as a therapeutic option in sickle cell crisis.
HGF/scatter factor is secreted by mesenchymal cells and
targets epithelial and endothelial cells [16]. It has a role in
angiogenesis, tissue regeneration, marrow reconstitution,
and the development of tumors. HGF is a good candidate as a
potential predictive marker for VOD (as well as GVHD). We
observed a surge in HGF 2 weeks ahead of the clinical diag-
nosis of VOD, and it remained elevated for 2 weeks subse-
quently. In children without complications after HSCT, HGF
stayed close to its baseline value throughout the 100 days
after transplantation. This baseline, however, was well above
concurrent control values.
Table 5
Partial Listing of Cytokine Activity Expressed as MFI
Cytokine Control Subjects (n ¼ 11) HSCT without Complications (n ¼ 33) GVHD (n ¼ 11) VOD (n ¼ 5) Respiratory Insufﬁciency (n ¼ 3) P
GM-CSF 216  28 121  74 216  349 69  51 129  104 .07
GRO-a 77  23 97  151 199  438 118  115 154  255 .32
HGF 170  63 547  512 882  725 1037  871 954  836 .01
IL-2 412  54 105  109 133  143 76  50 67  26 .30
IL-4 195  34 53  27 62  25 61  34 56  16 .48
IL-6 40  8 31  40 64  95 91  154 30  17 .01
IL-17F 425  58 116  62 190  267 88  24 113  37 .34
IFN-b 412  54 229  173 471  856 198  54 228  75 .40
IP-10 305  68 1197  1670 1639  2399 1622  2438 1600  1434 .73
MCP-1 367  93 1297  1652 2011  3648 2530  3510 1457  2137 .29
PAI 9055  748 8170  1861 8350  2147 9263  1712 7557  2714 .36
PDGFBB 1828  820 240  356 464  947 157  107 105  80 .13
TGF-b 250  35 58  43 61  37 46  17 54  26 .75
TNF-a 66  18 29  17 35  24 27  9 44  58 .12
VCAM1 2958  1161 6267  2628 6749  3007 8067  2990 8456  3893 .25
VEGF 131  60 71  56 86  66 98  48 56  57 .36
All clinical specimens were obtained at 7:00 AM 1 hour. Cytokine proﬁles for transplant recipients differed markedly from control subjects. Analysis by mixed
treatment by subjects ANOVA detected differences between transplant groups with and without complications only for GM-CSF, IL-6, and HGF.
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PAI-1, TNF-a, and IL-1b have previously been implicated
in VOD [17-19]. We found no similar association throughout
the 100 days after HSCT, during which time there was no
difference in the activity of PAI-1, TNF-a, and IL-1b in chil-
dren with eventual VOD as compared with the uncompli-
cated group. These 3 cytokines were not elevated compared
with concurrent control subjects.
Schots et al. [20] determined that high average levels
of IL-6, IL-8, and/or TNF-a within 10 days of HSCT were
independently associated with GVHD, VOD, or idiopathicFigure 6. Median ﬂuorescence activity. Number of weeks after transplantation along
complications (n ¼ 33, MFI e SD) dark gray band in foreground; GVHD (n ¼ 10, MFI e
background.pneumonia syndrome. Cutler et al. [21] found that certain
biomarkers of endothelial injury (von Willebrand Factor,
thrombomodulin, E-selectin, and soluble intercellular adhe-
sion molecule-1) were predictive of VOD in HSCT recipients
receiving sirolimus but not in others. In an in vitro setting,
Pihusch et al. [22] demonstrated that TGF-b1 released from
activated platelets might fuel the hemostatic imbalance at
the sinusoidal endothelium in hepatic VOD. In our surveil-
lance, childrenwith VODmanifested lower levels of multiple
cytokines (GM-CSF, IL-2, IL-4, IL-17F, PDGFBB, TGF-b) than in
the uncomplicated or GVHD groups, whereas HGF and IL-6the x-axis, with day of transplant samples collected at x ¼ 1. Patients without
SD) light gray with black outline; VOD (n ¼ 5) (MFI þ SD) medium gray band in
Figure 7. Receiver operating characteristic curves were constructed for pre-
diction of vaso-occlusive disease by MFI measured 21 days after trans-
plantation. HGF, GRO-a, and MCP-1 were superior to IL-6.
J. DiCarlo et al. / Biol Blood Marrow Transplant 20 (2014) 361e369368reached high plateau levels 1 to 2 weeks before the diagnosis
of VOD.Graft-versus-Host Disease
Harris et al. [23] recently demonstrated the utility of HGF
and another novel biomarker, designated as regenerating
islet-derived-3a, in the identiﬁcation and monitoring of
adults with liver and gastrointestinal tract GVHD. Through
high-throughput discovery methods similar to those used in
our study, Paczesny et al. [24] identiﬁed a quartet of potential
biomarkers of GVHD (IL-2 receptor a, TNF receptor 1, IL-8,Figure 8. Receiver operating characteristic curves were constructed for pre-
diction of GVHD by MFI measured 21 days after transplantation. HGF and GRO-
a demonstrated acceptable sensitivity but poor speciﬁcity.and HGF) and subsequently validated the panel in a large
population of HSCT recipients. The median age of this pop-
ulation was 43 years (range, 1 to 68), and patients with VOD
were excluded.
We did not measure IL2RA, but in our population IL-8
activity in children with eventual GVHD was indistinguish-
able from activity in recipients with eventual VOD or an
uncomplicated course. However, TNF-a and HGF activity
were high in the children who were eventually diagnosed
with GVHD. Receiver operating characteristic curves were
constructed for prediction of GVHD byMFI measured 21 days
after transplantation. HGF and GRO-a demonstrated
acceptable sensitivity but poor speciﬁcity (Figure 8).
CONCLUSIONS
From a longitudinal assay of 51 cytokines and chemo-
kines, we can postulate a characteristic pattern of cytokine
and chemokine secretion across the ﬁrst 100 days after HSCT
in children. Most cytokines are quiescent in the ﬁrst few
weeks after HSCT, coinciding with the induced nadir in the
WBC count. At the same time, however, there is a surge of
leptin, GRO-a, and MCP-1 in most recipients, whereas IL-6
and HGF surge in children with eventual major complica-
tions. After 4 weeks, resistin surges in all groups. Children
with eventual complications exhibit a general “signature” of
increased cytokine activity, but differences reach statistical
signiﬁcance with only a few speciﬁc entities. HGF has now
emerged in 3 or more biomarker discovery efforts for GVHD
(and in our population, for VOD as well). HGF (with or
without IL-6) should be investigated as a potential predictive
biomarker of VOD or GVHD. Alternatively, the hyper-
inﬂammatory “signature” provided by a multicytokine assay
may be predictive.
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